How it works, simply
It signals the pituitary gland to release growth hormone, increasing downstream IGF-1 signaling.
What the evidence tells us
It is not approved as a general weight-loss treatment. Increased IGF-1, glucose intolerance and fluid retention are relevant concerns.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Increased IGF-1, fluid retention and glucose intolerance require monitoring.
- Active malignancy and pregnancy are contraindications in the referenced label.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates growth hormone-releasing hormone receptors to increase endogenous growth-hormone signaling.
Sponsor or developer: Theratechnologies
Studied or labeled topics: Excess abdominal fat in adults with HIV-associated lipodystrophy
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: EGRIFTA WR prescribing information ↗ · Regulator · Aug 03, 2026
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.